Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats.
BACKGROUND
Human calcium oxalate (CaOx) nephrolithiasis may occur if urine is supersaturated with respect to the solid-phase CaOx. In these patients, dietary oxalate is often restricted to reduce its absorption and subsequent excretion in an effort to lower supersaturation and to decrease stone formation. However, dietary oxalate also binds intestinal calcium which lowers calcium absorption and excretion. The effect of increasing dietary oxalate on urinary CaOx supersaturation is difficult to predict.


METHODS
To determine the effect of dietary oxalate intake on urinary supersaturation with respect to CaOx and brushite (CaHPO4), we fed 36th and 37th generation genetic hypercalciuric rats a normal Ca diet (1.2% Ca) alone or with sodium oxalate added at 0.5%, 1.0%, or 2.0% for a total of 18 weeks. We measured urinary ion excretion and calculated supersaturation with respect to the CaOx and CaHPO4 solid phases and determined the type of stones formed.


RESULTS
Increasing dietary oxalate from 0% to 2.0% significantly increased urinary oxalate and decreased urinary calcium excretion, the latter presumably due to increased dietary oxalate-binding intestinal calcium. Increasing dietary oxalate from 0% to 2.0% decreased CaOx supersaturation due to the decrease in urinary calcium offsetting the increase in urinary oxalate and the decreased CaHPO4 supersaturation. Each rat in each group formed stones. Scanning electron microscopy revealed discrete stones and not nephrocalcinosis. X-ray and electron diffraction and x-ray microanalysis revealed that the stones were composed of calcium and phosphate; there were no CaOx stones.


CONCLUSIONS
Thus, increasing dietary oxalate led to a decrease in CaOx and CaHPO4 supersaturation and did not alter the universal stone formation found in these rats, nor the type of stones formed. These results suggest the necessity for human studies aimed at determining the role, if any, of limiting oxalate intake to prevent recurrence of CaOx nephrolithiasis.
Bushinsky
D A
DA
Nephrology Unit, University of Rochester, New York, USA. David_Bushinsky@urmc.rochester.edu
Bashir
M A
MA
Riordon
D R
DR
Nakagawa
Y
Y
Coe
F L
FL
Grynpas
M D
MD
D000818:Animals; D002118:Calcium / Q000652:urine*; D002129:Calcium Oxalate / Q000652:urine*; D002130:Calcium Phosphates / Q000652:urine; D004032:Diet; D005260:Female; D007477:Ions; D008297:Male; D009994:Osmolar Concentration; D010070:Oxalates / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014545:Urinary Calculi / Q000209:etiology / Q000473:pathology